Trial Profile
Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Zotarolimus (Primary)
- Indications Cardiovascular disorders; Coronary artery restenosis; Coronary disorders; Stent thrombosis
- Focus Therapeutic Use
- Acronyms ZEUS
- 01 Nov 2013 Study design published in American Heart Journal.
- 09 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Oct 2011 Additional trial locations (Hungary, Switzerland) identified as reported by ClinicalTrials.gov.